Characteristics and Trends in Hypnotics Consumption in the Largest Health Care System in Israel. - Wikidata - wikimedia - TriplyDB

Characteristics and Trends in Hypnotics Consumption in the Largest Health Care System in Israel.

Characteristics and Trends in Hypnotics Consumption in the Largest Health Care System in Israel.

http://www.wikidata.org/entity/Q37253959

about

Epidemic Use of Benzodiazepines among Older Adults in Israel: Epidemiology and Leverage Points for Improvement.Impact of a nurse-based intervention on medication outcomes in vulnerable older adults

P2860

Q38805648-49801AD4-E6D6-4A98-A6E7-E234951EE329 Q58761771-8AB4CDFF-69C8-4254-A0C7-843291564D56

P2860

Characteristics and Trends in Hypnotics Consumption in the Largest Health Care System in Israel.

http://www.wikidata.org/entity/Q37253959

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 31 August 2016

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Characteristics and Trends in ...... Health Care System in Israel.

@en

Characteristics and Trends in ...... Health Care System in Israel.

@nl

type

label

Characteristics and Trends in ...... Health Care System in Israel.

@en

Characteristics and Trends in ...... Health Care System in Israel.

@nl

prefLabel

Characteristics and Trends in ...... Health Care System in Israel.

@en

Characteristics and Trends in ...... Health Care System in Israel.

@nl

P1433

Q37253959-0063FB0B-50FF-4311-83A3-00BB89B9A54A

P1476

Q37253959-A4B9676F-20BC-43EC-ADFC-EBFC30D86D8C

P2093

Q37253959-00F9190B-E152-4804-A4CF-5E4D5DBE320B

Q37253959-768A513F-85DD-4375-9B36-BA477DF9AC94

Q37253959-A332FAB1-4DF0-4D4E-B9E3-56C15ED08893

P2860

Q37253959-012A991D-28B9-4177-98E6-8BB88B49EA95

Q37253959-0B0ED26E-0BDA-4371-8122-29981989F8AD

Q37253959-106E1662-ED4E-41D1-BCAF-428B53252A52

Q37253959-10FE970A-3EBE-46D9-802A-FDB78D68968D

Q37253959-114027CE-F7E0-4371-ACA1-890B5FEE71E4

Q37253959-17AE6C2A-8282-4E44-BEB9-4BDAA36AE61B

Q37253959-3B2C8A41-3C6A-4785-A9CC-BA4FD779E9EF

Q37253959-43028107-C249-4249-AE32-34C053F1B194

Q37253959-4DB0459B-57AE-403E-8E90-8DF67112F2F9

Q37253959-576CBB7A-AAE4-469F-AFF1-4BACC4BDFF2B

P304

Q37253959-5CE658CD-D09A-4B02-8E3E-EBCD5F302DE4

P31

Q37253959-55938437-CBEE-421B-BBC4-D1B635221EDD

P356

Q37253959-AF0512EF-E9EC-4413-A586-90376D74CC71

P478

Q37253959-0E5F5E90-6DCA-4419-9E99-40D60803849D

P50

Q37253959-676740AD-7D61-4044-B4A3-6373651D3DF4

Q37253959-940CDD0E-7C26-4C8E-A086-E43F6C1F3912

P577

Q37253959-CE8E7AC9-D13D-441C-BF73-E94BC7FEC46B

P698

Q37253959-9BB692BA-855C-47DC-8234-8AD495515DB5

P921

Q37253959-4B7AA567-FC13-41D5-A808-D9E80BB9897D

P932

Q37253959-51F1F63D-28E8-4A97-82C0-F58CF2BEF435

P356

P1433

Sleep disorders

P1476

Characteristics and Trends in ...... Health Care System in Israel.

@en

P2093

G Rennert

http://www.w3.org/2001/XMLSchema#string

K Landsman

http://www.w3.org/2001/XMLSchema#string

N Stein

http://www.w3.org/2001/XMLSchema#string

P2860

Financial incentive increases CPAP acceptance in patients from low socioeconomic background

Insomnia with objective short sleep duration and incident hypertension: the Penn State Cohort.

The Effect of the Transition to Home Monitoring for the Diagnosis of OSAS on Test Availability, Waiting Time, Patients' Satisfaction, and Outcome in a Large Health Provider System

Sedative medication use: prevalence, risk factors, and associations with body mass index using population-level data.

Association between insomnia symptoms and hemoglobin A1c level in Japanese men

British Association for Psychopharmacology consensus statement on evidence-based treatment of insomnia, parasomnias and circadian rhythm disorders.

Risk of dementia in patients with insomnia and long-term use of hypnotics: a population-based retrospective cohort study.

Determinants of elevated healthcare utilization in patients with COPD

Efficacy without tolerance or rebound insomnia for midazolam and temazepam after use for one to three months.

Mortality hazard associated with anxiolytic and hypnotic drug use in the National Population Health Survey.

P304

8032528

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1155/2016/8032528

http://www.w3.org/2001/XMLSchema#string

P478

2016

http://www.w3.org/2001/XMLSchema#string

P50

P577

2016-08-31T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27660727

http://www.w3.org/2001/XMLSchema#string

P921

P932

5021873

http://www.w3.org/2001/XMLSchema#string